journal article·2026-01Open access

Affinity‐Based Protein Profiling Revealed that HIGD1A is a Direct Target Protein of Aristolochic Acids

Yin Gong, Shanshan Zhang, Anying Wei, Xiang Ji, Xiaodan Chong, Jinfeng Cen, Xuan Zhao, Zimeng Luo, Zhipeng Pei, Guanchao Mao, Xinkang Zhang, Mingxue Sun, Zhiguo Sun, Zifei Yin, Zhengrong Zou, Wen‐Qi Meng

Advanced Science· Volume 13· Issue 5

Abstract

Abstract Exposure to aristolochic acids (AA) via the ingestion of AA‐containing medicine or food is a significant risk factor for severe nephropathy. Despite decades of research, the direct molecular targets underlying AA toxicity remain elusive. In this study, a map of the AA‐binding protein atlas in kidney tissues is constructed via the design and synthesis of an AA‐based affinity probe. Among the AA‐binding proteins, HIGD1A is identified as a high‐affinity AA target (SPR: 59.6 n m ; ITC: 195 n m ) with significant thermostability changes upon AA binding. Furthermore, AA disrupted the HIGD1A‐TFAM interaction, triggering TFAM degradation via the autophagy‐lysosome pathway. This led to the accumulation of cytosolic mitochondrial DNA. This study also suggested that HIGD1A also contributed to AA‐induced inflammation by increasing the cytosolic levels of oxidized mitochondrial DNA to activate the MAPK and NF‐κB pathways. This study not only reveals an important target protein of AA but also provides novel inspiration and ideas for toxicology and chemical biology research.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nephrotoxicity and Medicinal Plants · Traditional Chinese Medicine Analysis · Nigella sativa pharmacological applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Naval Medicine Naval Military Medical University Shanghai China

College of Life Sciences Jiangxi Normal University Nanchang 330022 China

School of Traditional Chinese Medicine Naval Medical University Shanghai 200433 China

Clinical Cancer Institute Translational Medicine Center Faculty of Pharmacy Naval Medical University Shanghai 200433 China

Department of Pharmaceutical Science Faculty of Pharmacy Naval Medical University Shanghai 200433 China

Funding

National Natural Science Foundation of China · Shanghai Rising-Star Program

References (45)

Show source-provided references
1. 10.1111/bph.1561810.1111/bph.15618 ↗
2. 10.7554/eLife.8974010.7554/eLife.89740 ↗
3. 10.3390/ijms2103115710.3390/ijms21031157 ↗
4. 10.1016/0140-6736(93)92984-210.1016/0140-6736(93)92984-2 ↗
5. 10.1016/S0140-6736(94)90964-410.1016/S0140-6736(94)90964-4 ↗
6. 10.2215/CJN.1239121410.2215/CJN.12391214 ↗
7. 10.1111/jcpt.1278910.1111/jcpt.12789 ↗
8. 10.1016/j.kint.2023.09.02010.1016/j.kint.2023.09.020 ↗
9. 10.1038/s41586-025-09219-010.1038/s41586-025-09219-0 ↗
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans · 2002
11. 10.1038/s41586-024-07054-310.1038/s41586-024-07054-3 ↗
12. Sun M. X. · Biol. Med. · 2023 · 204 · 313
13. 10.1136/bmj.e400010.1136/bmj.e4000 ↗
14. 10.1080/15548627.2023.228793010.1080/15548627.2023.2287930 ↗
15. 10.1111/bph.1629910.1111/bph.16299 ↗
16. 10.3390/ijms1810214410.3390/ijms18102144 ↗
17. 10.1021/acs.chemrestox.1c0017510.1021/acs.chemrestox.1c00175 ↗
18. 10.1016/j.tiv.2011.01.01610.1016/j.tiv.2011.01.016 ↗
19. 10.1016/j.toxlet.2019.04.02710.1016/j.toxlet.2019.04.027 ↗
20. 10.1152/ajprenal.00675.200910.1152/ajprenal.00675.2009 ↗
21. 10.1016/j.cell.2022.12.00410.1016/j.cell.2022.12.004 ↗
22. 10.1038/s41586-022-04431-810.1038/s41586-022-04431-8 ↗
23. 10.1126/science.123360610.1126/science.1233606 ↗
24. 10.1038/ki.2008.12910.1038/ki.2008.129 ↗
25. 10.1021/acs.chemrestox.2c0037010.1021/acs.chemrestox.2c00370 ↗
26. 10.1093/nar/gkp81510.1093/nar/gkp815 ↗
27. 10.3389/fphar.2020.62452910.3389/fphar.2020.624529 ↗
28. 10.1007/s13577-019-00306-910.1007/s13577-019-00306-9 ↗
29. 10.1038/s41392-020-00389-z10.1038/s41392-020-00389-z ↗
30. 10.1038/s41419-019-2197-610.1038/s41419-019-2197-6 ↗
31. 10.1038/s41598-017-09648-610.1038/s41598-017-09648-6 ↗
32. 10.3390/antiox1202039710.3390/antiox12020397 ↗
33. 10.1007/s00204-019-02572-w10.1007/s00204-019-02572-w ↗
34. 10.1007/s00204-020-02656-y10.1007/s00204-020-02656-y ↗
35. 10.1016/j.cell.2024.02.01410.1016/j.cell.2024.02.014 ↗
36. 10.1007/s00204-024-03799-y10.1007/s00204-024-03799-y ↗
37. 10.1016/S0140-6736(18)30727-X10.1016/S0140-6736(18)30727-X ↗
38. 10.1016/j.redox.2023.10293010.1016/j.redox.2023.102930 ↗
39. 10.1016/S0140-6736(20)32644-110.1016/S0140-6736(20)32644-1 ↗
40. 10.1016/j.jhazmat.2020.12481110.1016/j.jhazmat.2020.124811 ↗
41. 10.1016/j.celrep.2023.11273110.1016/j.celrep.2023.112731 ↗
42. 10.1016/j.celrep.2015.01.02010.1016/j.celrep.2015.01.020 ↗
43. 10.1038/s41467-023-39050-y10.1038/s41467-023-39050-y ↗
44. 10.1016/j.metabol.2022.15524110.1016/j.metabol.2022.155241 ↗
45. 10.1038/s41388-022-02226-910.1038/s41388-022-02226-9 ↗